Using the industry peer median EV/EBITDA multiple (trailing + forward), Amicus Therapeutics, Inc. (FOLD) has a fair value of $3.44 based on 2 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/EBITDA | Forward EV/EBITDA | |
|---|---|---|---|
| Amicus Therapeutics, Inc.FOLD | 4,468 | 88.0x | 74.1x |
| Kiniksa Pharmaceuticals, Ltd. | 3,996 | 42.5x | 31.5x |
| Catalyst Pharmaceuticals, Inc. | 3,595 | 9.0x | 8.4x |
| Industry Median | 25.7x | 20.0x | |
| (*) EBITDA | 54 | 64 | |
| = Enterprise Value | 1,385 | 1,276 | |
| (-) Net Debt | 269 | 269 | |
| Equity Value | 1,115 | 1,007 | |
| (/) Outstanding shares | 308 | 308 | |
| Fair Price | $4 | $3 | |
Using the industry peer median EV/Revenue multiple (trailing + forward), Amicus Therapeutics, Inc. (FOLD) has a fair value of $11.54 based on 8 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Amicus Therapeutics, Inc.FOLD | 4,468 | 7.5x | 6.3x |
| Scholar Rock Holding Corporation | 5,368 | 160.7x | — |
| Legend Biotech Corporation | 4,357 | 3.8x | 2.7x |
| Kiniksa Pharmaceuticals, Ltd. | 3,996 | 5.7x | 4.2x |
| Catalyst Pharmaceuticals, Inc. | 3,595 | 4.9x | 4.6x |
| Arcutis Biotherapeutics, Inc. | 2,889 | 7.6x | 5.7x |
| Tarsus Pharmaceuticals, Inc. | 2,642 | 5.7x | 3.7x |
| IDEAYA Biosciences, Inc. | 2,553 | 11.3x | 70.9x |
| Adaptive Biotechnologies Corporation | 2,162 | 8.6x | 8.4x |
| Industry Median | 6.6x | 4.6x | |
| (*) Revenue | 634 | 754 | |
| = Enterprise Value | 4,202 | 3,453 | |
| (-) Net Debt | 269 | 269 | |
| Equity Value | 3,933 | 3,183 | |
| (/) Outstanding shares | 308 | 308 | |
| Fair Price | $13 | $10 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.